Desmopressin Acetate Production Cost Reports

The report provides a detailed analysis essential for establishing a desmopressin acetate production plant. It encompasses all critical aspects necessary for desmopressin acetate production, including the cost of desmopressin acetate production, desmopressin acetate plant cost, desmopressin acetate production costs, and the overall desmopressin acetate production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a desmopressin acetate production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Desmopressin acetate is a synthetic, long-acting analogue of the human hormone arginine vasopressin (anti-diuretic hormone). It functions as an active pharmaceutical ingredient (API) in production formulations like nasal sprays, oral tablets, and injectable solutions to treat conditions such as central diabetes insipidus, nocturnal enuresis, haemophilia A, and von Willebrand's disease. In industrial production processes, it undergoes rigorous analytical method validation, stability testing, and quality control to meet regulatory standards for abbreviated new drug applications (ANDAs) and commercial-scale synthesis. Additionally, research explores advanced drug delivery systems incorporating desmopressin acetate, including mucoadhesive emulsions, submicron particles, transdermal liposomes, and rapidly dissolving buccal tablets to enhance bioavailability, patient compliance, and controlled release for nocturia or bleeding disorder management.

Desmopressin acetate's market growth is driven by the rising prevalence of conditions like diabetes insipidus, nocturnal enuresis, haemophilia A, von Willebrand's disease, and nocturia, fuelled by ageing populations, lifestyle factors, and improved diagnostics. The healthcare infrastructure expansion and increased accessibility in emerging markets, mainly Asia-Pacific (e.g., China and India), along with government subsidies and higher spending, boost adoption rates. Advancements in formulations, such as oral tablets, nasal sprays, and injections, along with R&D for better delivery systems, enhancing patient compliance, further propel demand. However, high production costs for advanced formulations, competition from alternative therapies for conditions like diabetes insipidus, and low end-user concentration due to the drug's niche applications impact industrial desmopressin acetate procurement.

Raw Material for Desmopressin Acetate Production

According to the desmopressin acetate production plant project report, the various raw materials for desmopressin acetate production include Fmoc-protected amino acids.

Production Process of Desmopressin Acetate

The extensive desmopressin acetate production cost report consists of the following major industrial production process:

1. Production via solid-phase peptide synthesis: The production process of desmopressin acetate occurs through solid-phase peptide synthesis (SPPS) of its cyclic octapeptide sequence. The process starts with sequential Fmoc-protected amino acid coupling on resins like Sieber amide or wang using agents such as DIC/HOBt in DMF/NMP, followed by piperidine deprotection and washing cycles. The linear peptide is cleaved from resin with TFA-based cocktails, precipitated, and purified via reversed-phase HPLC with acetate/acetonitrile gradients, followed by cyclisation in liquid phase using iodine or ferricyanide oxidation to form disulfide bridges, achieving ~92% purity. The final purification employs RP-HPLC with acetate buffers for salt exchange to produce GMP-grade API (>99% purity) after lyophilisation, optimising yield, cost, and scalability for pharmaceutical use.

Properties of Desmopressin Acetate

Desmopressin acetate is a synthetic vasopressin analogue used in pharmaceutical production as an API for formulations like nasal sprays, tablets, and injections to treat diabetes insipidus, nocturnal enuresis, haemophilia A, and nocturia. It appears in a white to off-white hygroscopic powder form, with high water solubility (>100 mg/mL), a melting point of 170-172 degrees Celsius (with decomposition), and slight solubility in methanol or acetic acid. It has the molecular formula C46H64N14O12S2·C2H4O2, molecular weight ~1129.3 g/mol, a cyclic structure with disulfide bridges, and stability under -20 degrees Celsius storage.